The ongoing Phase II trial investigates the efficacy of Apatorsen (OGX-427), an antisense oligonucleotide targeting Hsp27, in combination with standard chemotherapy (gemcitabine/carboplatin) for patients with advanced squamous cell lung cancer (NSCLC). Given the limited treatment options for this patient population, successful outcomes could position Apatorsen as a novel therapeutic option, potentially enhancing the effectiveness of existing chemotherapy regimens. The market for lung cancer treatments is substantial, with increasing demand for innovative therapies. Competitive analysis indicates that while several therapies are available, few specifically target Hsp27, suggesting a unique market position if clinical efficacy is demonstrated. Diligence should focus on the trial's recruitment status, safety profile, and competitive landscape, particularly regarding other emerging therapies targeting similar pathways.